

INDE 217: Physician Scientist Hour		
PhySH schedule for 2019-2020		
Autumn Quarter 2019		
9/23/19	Carla Schatz	MSOB x303
9/30/19	TIP residency	MSOB x303
10/7/19	Mental Health: Ned Morris	MSOB x303
10/14/19	Judith Frydman	MSOB x303
10/21/19	Ron Davis	LK 205/206
10/28/19	Matt Porteus	MSOB x303
11/4/19	Raag Airan	MSOB x303
11/11/19	Lingyin Li	MSOB x303
11/18/19	Town Hall	LKSC 130
Winter Quarter 2020		
1/13/20	Stanley Qi	LK 120
1/27/20	Paul Khavari	MSOB x303
2/3/20	Catherine: F30	LK 130
2/10/20	Kari Nadeau	LK 130
2/24/20	John Boothroyd	LK 130
3/2/20	Robin Lorenz	MSOB x303
3/9/20	[Cancelled]	LK 120
Spring Quarter 2020		
3/30/20	[Cancelled]	
4/6/20	[Cancelled]	
4/13/20	[Cancelled]	
4/20/20	[Cancelled]	
4/27/20	Catherine Blish	Zoom
5/4/20	M4 Panel: Ben Dulken, Benson George, Lichy Han, Grant Lin, Surya Nagaraja & Zahra Sayyid	Zoom
5/11/20	Mark Kay, Carrie Rossback & Zachary Sellers	Zoom
5/18/20	Margaret Guo & Anthony Cordova	Zoom
6/1/20	[Cancelled]	

Autumn 2019 PhySH Schedule

Carla Shatz

September 23, 2019 in MSOB X303

Dr. Shatz's research aims to understand how early developing brain circuits are transformed into adult connections during critical periods of development. Her work, which focuses on the development of the mammalian visual system, has relevance not only for treating disorders such as autism and schizophrenia, but also for understanding how the nervous and immune systems interact.

Joy Wu and Josh Knowles

September 30, 2019 in MSOB X303

Residency Focus: Stanford's Translational Investigator Program (TIP)

The goal of Stanford's Translational Investigator Program (TIP) is to provide unparalleled training and mentorship for individuals

Ned Morris

October 7, 2019 in MSOB X303

Mental Health Focus

Nathaniel (Ned) Morris, MD is a graduate of Cornell University and Harvard Medical School. He is currently Chief Resident for Stanford Inpatient Psychiatry at the Stanford University School of Medicine. He enjoys writing about medical education, health policy, and topics related to mental health.

Judith Frydman

October 14, 2019 in MSOB X303

Dr. Frydman's research is on understanding on proteins and how they fold in living cells. Her lab uses a multidisciplinary approach to address fundamental questions about molecular chaperones, protein folding and degradation. In addition to basic mechanistic principles, her lab aims to define how impairment of cellular folding and quality control are linked to disease, including cancer and neurodegenerative diseases and examine whether reengineering chaperone networks can provide therapeutic strategies

Ron Davis

October 21, 2019 in LKSC 205/206

Dr. Davis' pivotal contributions to molecular genetics and genomics include many firsts that have transformed both fields. Back in 1980, in one of the most highly cited papers in human genetics, he and his colleagues pioneered a way to scan a whole genome to pinpoint the location of genes. This launched the field of genomics and paved the way for genetically targeted medical treatments. Dr. Davis also invented a technique to identify genes that code for key proteins, and helped discover the genes for color vision and color blindness. He also collaborated on the first DNA microarray for profiling thousands of genes simultaneously and helped automate the process to reduce the cost for clinical applications. After that he contributed to sequencing the first eukaryotic genome for baker's yeast.

Matt Porteus

October 28, 2019 in MSOB X303

Finding Synergy between your Research Interests and Clinical Interest

Dr. Porteus is an Associate Director of the Stanford MSTP program. His research focuses on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle.

Raag Airan

November 4, 2019 in MSOB X303

The goal of Dr. Airan's research is to develop and clinically implement new technologies for high-precision and noninvasive intervention upon the nervous system. Every few millimeters of the brain is functionally distinct, and different parts of the brain may have counteracting responses to therapy. To better match the therapies developed by Dr. Airan's group to neuroscience, they develop techniques that allow intervention upon only the right part of the nervous system at the right time, using technologies like focused ultrasound and nanotechnology.

Lingyin Li

November 11, 2019 in MSOB X303

Dr. Li's research combines chemistry, biochemistry, immunology, and physiology. Dr. Li has been an assistant professor in the Biochemistry Department and ChEM-H Institute at Stanford since 2015. Her lab works on understanding the biochemical mechanisms of innate immunity and harnessing them to treat cancer. She majored in Chemistry at the University of Science and Technology of China and graduated with a B. En in 2003. For graduate training in Chemistry, she worked with Dr. Laura Kiessling, a pioneer in Chemical Biology, at the University of Wisconsin-Madison. Dr. Li completed her postdoctoral training with Dr. Timothy Mitchison at Harvard Medical School, who introduced her to the field of chemical immunology. Currently, Dr. Li's research group is using chemical biology to uncover biochemical mechanisms in innate immunity and, in parallel, develop therapeutic hypotheses and lead compounds.

PhySH Town Hall

November 18, 2019 in LKSC 130

Winter 2020 PhySH Schedule

Stanley Qi

January 13, 2020 in LKSC 120

Dr. Qi is a pioneer in the development of genetic engineering technologies, broadly defined, for controlling, manipulating, and engineering the genetic codes of life. He and his research group believe that the ability to control the genome is of fundamental importance to understanding its function in physiology and disease, which provides a foundation for rationally designing and engineering the genome and cells for diagnosis and therapeutics. They regard such an approach as discovery-based synthetic biology. Towards this goal, they have developed the nuclease-deactivated Cas9 (dCas9) molecule from the prokaryotic CRISPR system for multiple purposes: CRISPRi/a for transcription activation or repression, genome imaging for genome tracking in living cells, and CRISPR-GO for manipulating the 3D genome organization in the nucleus.

Paul Khavari

January 27, 2020 in MSOB X303

Dr. Khavari's research is on genome regulation in stem cell differentiation and cancer. He uses genomics and proteomics-based approaches combined with veridical genetic models and biocomputation to identify new regulators and networks that regulate these processes. Integral to these efforts is development of new molecular therapeutics for human disease.

Catherine Blish

February 3, 2020 in LKSC 130

Grant Writing: F30

Dr. Blish's research is on infectious diseases. She is a Chan Zuckerberg BioHub Investigator and is an Associate Director of the Stanford MSTP program.

Kari Nadeau

February 10, 2020 in LKSC 130

Translating Molecular Signals to Cures

Dr. Nadeau is the Naddisy Foundation Endowed Professor of Medicine and Pediatrics and, Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She is Section Chief in asthma and allergy in Pulmonary and Critical Care at Stanford.

John Boothroyd

February 24, 2020 in LKSC 130

Managing up, down and across: how to have productive, stress-free relationships at work

Dr. Boothroyd's research interests have spanned from viruses such as bacteriophage T7 and Foot and Mouth Disease Virus through to protozoan parasites such as *Trypanosoma brucei*, the cause of African sleeping sickness, and *Toxoplasma gondii*, a serious pathogen in newborns and individuals who are immunocompromised.

Robin Lorenz

March 2, 2020 in MSOB X303

Perspectives on balancing a career as a physician-scientist

Dr. Lorenz is the Senior Director in the Department of Pathology at Genentech, Inc. Her department provides pathology support to laboratory and clinical scientists engaged in biomarker strategy/development/deployment across the drug development pipeline.

Spring 2020 PhySH Schedule

Catherine Blish

April 27, 2020 (via Zoom)

Update on Her Work on COVID-19

Dr. Blish's research is on infectious diseases. She is a Chan Zuckerberg BioHub Investigator and is an Associate Director of the Stanford MSTP program.

M4 Panel: Ben Dulken, Benson George, Lichy Han, Grant Lin, Surya Nagaraja & Zahra Sayyid

May 4, 2020 (via Zoom)

M4 Student Panel Discussion: Applying for clerkship, transitioning to clerkship, applying for residency + more!

Mark Kay, Carrie Rassbach & Zachary Sellers

May 11, 2020 (via Zoom)

Mark Kay, MD, PhD, Zack Sellers, MD, PhD, and Carrie Rassbach, MD, MA, will be presenting about the highlights of the Stanford Pediatrics Residency's Physician-Scientist Track, including the field of Pediatrics, Research in the Department of Pediatrics, the Residency Program's Research Pathways, graduates' career paths, and more. The Physician-Scientist Track was started in 2011 and is among the top pediatrics residency training programs for physician-scientist residents in the country.

Dr. Kay's research is on the development of gene transfer vectors for gene therapy as well as manipulating non-coding RNAs for therapeutic purposes. Dr. Rassbach focuses on medical education including learner assessment, program development and mentoring and coaching in medicine. Dr. Sellers is pediatric physician-scientist striving to advance cystic fibrosis clinical care and translational research.

G2 Presentations: Margaret Guo; Anthony Cordova

May 18, 2020 (via Zoom)